Carevive Introduces Carevive SMART Data™ to Highlight the Real-World Oncology Patient Experience

On September 23, 2021  Carevive Systems (Carevive), the leading oncology-focused health technology company centered on understanding and improving the experience of patients with cancer, reported that launched Carevive SMART Data, a dataset containing information from patients about their experience with treatment, combined with demographic and clinical data (Press release, Carevive Systems, SEP 23, 2021, View Source [SID1234590367]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

As the healthcare industry becomes more saturated with big data, the search continues for data that can inform decisions that positively impact the experience and outcomes of patients with cancer. Big data, defined by large datasets with substantial numbers of patients and a wide array of clinical and claims data, can support certain types of statistical analyses. However, these datasets are limited because their datapoints are discrete, providing only sequential snapshots of a patient’s health status, without a more continuous assessment of the patient’s experience on treatment, which can only originate from the patients themselves.

In response to the need for this type of dataset, Carevive uses its digital oncology platform to collect information from patients about their experience at weekly time points during treatment. These data are combined with demographic and clinical data to create Carevive SMART Data (Symptom Monitoring with Applied Remote Technology).

Carevive SMART Data

Carevive SMART Data are captured as part of Carevive OPT-IN. Carevive OPT-IN, the Oncology Pragmatic Trial Investigator Network, enables patient experience data to be collected from real-world patients who are receiving treatment for cancer. Carevive OPT-IN began in late 2020 to amplify the patient voice in their own care and improve their outcomes. Carevive SMART Data are collected as part of an ongoing, weekly conversation between the patient and their care team, facilitated by Carevive’s cloud-based, digital oncology platform that patients can access with a variety of devices, from any location. Providing patients with remote symptom monitoring enables longitudinal data to be collected describing the holistic patient experience, including symptoms, quality of life, physical function, and healthcare resource utilization.

Licenses to Carevive SMART Data are available for life science companies who would like to analyze patient-centric data combining longitudinal patient-reported outcomes (PRO) with EHR-derived clinical data. By listening to the patient’s voice in cancer care, Carevive can now address many important questions about the patient experience in cancer which have not been answered by big data.

Mordecai Kramer, Carevive’s Vice President of Data Generation & Outcomes, Life Sciences, summarizes the value of this novel dataset as follows: "We are excited about Carevive SMART Data and the holistic view of the patient experience that it provides. Since launching our registries, we are already seeing the value this longitudinal dataset creates for improving patient care and outcomes. We invite life science companies to join the Carevive SMART Data conversation and, together, answer pressing questions about real-world patients with cancer."

Scopus BioPharma to Present at the Benzinga Healthcare Small Cap Conference

On September 23, 2021 Scopus BioPharma Inc. (Nasdaq: "SCPS"), a clinical-stage biopharmaceutical company developing transformational therapeutics for serious diseases with significant unmet medical need, reported it will be presenting at the Benzinga Healthcare Small Cap Conference on Wednesday, September 29, 2021 (Press release, Scopus BioPharma, SEP 23, 2021, View Source [SID1234590205]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The company will present on the launch of Duet Therapeutics, its wholly-owned subsidiary focused on immuno-oncology. Scopus announced the launch of Duet on September 2, 2021.

Alan Horsager, Ph.D., President — Immuno-Oncology of Scopus and President and Chief Executive Officer of Duet, will be presenting on behalf of the company. Dr. Horsager’s presentation will be part of the Green Track on Wednesday, September 29, 2021. The presentation will be streamed live beginning at 4:20 PM EST and will be accessible by clicking here.

If you are an institutional investor interested in scheduling a one-on-one meeting with the company, please click here to register for the conference and request a one-on-one meeting.

About the Duet Platform

Duet Therapeutics integrates the immunotherapy assets of Scopus and Olimmune, creating the Duet Platform. Olimmune was acquired by Scopus in June 2021. Duet is a wholly-owned subsidiary of Scopus.

The Duet Platform is comprised of three distinctive, complementary CpG-STAT3 inhibitors:

• RNA silencing CpG-STAT3siRNA ("DUET-01")

• Antisense CpG-STAT3ASO ("DUET-02")

• DNA-binding inhibitor CpG-STAT3decoy ("DUET-03")

DUET-01 is in a Phase 1 clinical trial, as a monotherapy, for B-cell non-Hodgkin lymphoma. Duet expects to file two INDs for DUET-02 in Q4 2022 in genitourinary and head & neck cancers, with clinical Phase 1 trials beginning in Q1 2023 in the United States. Duet is also evaluating combination therapies with checkpoint inhibitors.

Boundless Bio to Present at the 2021 Cantor Fitzgerald Virtual Global Healthcare Conference

On September 23, 2021 Boundless Bio, a next-generation precision oncology company developing innovative therapeutics directed against extrachromosomal DNA (ecDNA) in aggressive cancers, reported that Chief Executive Officer, Zachary Hornby, will present at the 2021 Cantor Fitzgerald Virtual Global Healthcare Conference on Wednesday, September 29th, 2021, from 1:20-1:50 p.m. ET (Press release, Boundless Bio, SEP 23, 2021, View Source [SID1234590227]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!


Nature BioPharma Dealmakers Feature Article: Revitope—third-generation T cell engager immunotherapies

On September 23, 2021 Revitope Oncology, Inc. is a privately owned company in Cambridge, MA, reported that focuses on the development of next-generation T cell engager immunotherapies for a variety of solid cancer indications (Press release, Revitope Oncology, SEP 23, 2021, View Source [SID1234591881]). Revitope’s platform is a suite of proprietary and modular bispecific antibodies designed to deliver improved therapeutic efficacy and safety through built-in control mechanisms that enable exquisite tumor-specificity. The company has several cancer programs in preclinical development and expects to have its lead program in the clinic by early 2023.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

bioAffinity Technologies Announces Award of Therapeutic Patent for Treatment of Cancer

On September 23, 2021 bioAffinity Technologies, a privately held biotech company, reported that the Australian Patent Office issued a Notice of Acceptance for bioAffinity subsidiary OncoSelect’s patent protecting compositions and methods to treat cancer using chemotherapeutic agents conjugated to porphyrins, resulting in targeted delivery of the drugs (Press release, BioAffinity Technologies, SEP 23, 2021, View Source [SID1234590228]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"bioAffinity is focused on being the leader in research, development and commercialization of porphyrin-based diagnostics and therapeutics to detect cancer early and treat cancer specifically"

The patent, titled "Porphyrin Compounds and Compositions Useful for Treating Cancer," will be the Company’s first awarded therapeutic patent. In addition to the Australian patent, bioAffinity and its subsidiary OncoSelect have 18 patent applications filed to protect therapeutic discoveries. bioAffinity also holds 17 awarded patents and eight patent applications related to its porphyrin-based diagnostic platform.

"bioAffinity is focused on being the leader in research, development and commercialization of porphyrin-based diagnostics and therapeutics to detect cancer early and treat cancer specifically," said bioAffinity President and CEO Maria Zannes. "We successfully developed our highly accurate CyPath Lung test for the early detection of lung cancer. Our test is based on the fluorescent porphyrin TCPP’s remarkable ability to bind to cancer and cancer-associated cells that can be detected by flow cytometry using automated analysis."

bioAffinity’s research to support the CyPath diagnostic platform has led to multiple discoveries related to cancer therapeutics, including use of novel compositions to attach chemotherapy drugs to porphyrins for targeted delivery into the tumor cell, with a much less deleterious effect on normal cells. Yet another discovery has led to the successful use of RNA interference to knock down expression of two genes that results in killing cancer cells with little or no effect on normal cells.

"We have built upon our diagnostic research to develop a diverse number of targeted therapeutics and provide novel life-saving strategies in the fight against cancer," Zannes said. "The Notice of Acceptance of this patent application not only protects our groundbreaking discoveries but also validates the strength of our science."